1. 180PPalbociclib in daily clinical use: Real world experience of the breast center at the University Hospital Munich. (13th May 2019) Authors: Hester, A; Koenig, A; Dobler, F; Degenhardt, T; Heidegger-Steger, H; Kurt, A-G; Kahlert, S; Mahner, S; Harbeck, N; Wuerstlein, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 964PPreoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer. (23rd October 2018) Authors: Braicu, E I; Sehouli, J; Richter, R; Vergote, I B; Concin, N; van Nieuwenhuysen, E; Achimas, P; Berger, A; Fetica, B; Mahner, S; Glajzer, J; Papadia, A; Woelber, L; Gasparri, M L; Vanderstichele, A; Benedetti Panici, P; Mueller, M; Ruscito, I; Zimmer, J; Woopen, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical management of borderline ovarian tumors. Issue 7 (July 2010) Authors: Trillsch, F; Mahner, S; Ruetzel, JD; Harter, P; Ewald-Riegler, N; Jaenicke, F; du Bois, A Journal: Expert review of anticancer therapy Issue: Volume 10:Issue 7(2010) Page Start: 1115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome. Issue 2 (29th November 2011) Authors: Woelber, L; Hess, S; Bohlken, H; Tennstedt, P; Eulenburg, C; Simon, R; Gieseking, F; Jaenicke, F; Mahner, S; Choschzick, M Journal: Journal of clinical pathology Issue: Volume 65:Issue 2(2012) Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EP1168 The influence of obesity on tumor recurrence in vulvar cancer patients. (1st November 2019) Authors: Klapdor, R; Hillemanns, P; Wölber, L; Jückstock, J; Hilpert, F; de Gregorio, N; Hasenburg, A; Sehouli, J; Fürst, ST; Strauß, HG; Baumann, K; Thiel, F; Mustea, A; Meier, W; Harter, P; Wimberger, P; Hanker, L; Schmalfeldt, B; Mahner, S Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?. (4th June 2018) Authors: Fotopoulou, C; Sehouli, J; Mahner, S; Harter, P; Van Nieuwenhuysen, E; Gonzalez-Martin, A; Vergote, I; Chiva, L; Du Bois, A Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1610 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. (1st November 2019) Authors: Mirza, MR; Dørum, A; Benigno, B; Mahner, S; Bessette, P; Bover Barcelo, IM; Berton, D; Ledermann, J; Rimel, BJ; Herrstedt, J; Lau, S; Canzler, U; Palacio Vázquez, I; Kalbacher, E; Buscema, J; Lorusso, D; Debruyne, P; Bruchim, I; Guo, W; Gupta, D Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P193 p53 and p16 expression profiles identify three prognostically subgroups in vulvar cancer: a TMA based study by the AGO-CaRE-translational study group. (1st November 2019) Authors: Wölber, L; Prieske, K; Eulenburg, C; de Gregorio, N; Klapdor, R; Kalder, M; Braicu, I; Fuerst, S; Klar, M; Strauss, H-G; Mehlhorn, G; Meier, W; Ignatov, A; Mustea, A; Jueckstock, J; Schmidt, G; Bauerschlag, D; Hellriegel, M; Canzler, U; Luyten, A Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Safety and dose modification for patients receiving niraparib. (13th August 2018) Authors: Berek, J S; Matulonis, U A; Peen, U; Ghatage, P; Mahner, S; Redondo, A; Lesoin, A; Colombo, N; Vergote, I; Rosengarten, O; Ledermann, J; Pineda, M; Ellard, S; Sehouli, J; Gonzalez-Martin, A; Berton-Rigaud, D; Madry, R; Reinthaller, A; Hazard, S; Guo, W Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Safety and dose modification for patients receiving niraparib. (14th May 2018) Authors: Berek, J S; Matulonis, U A; Peen, U; Ghatage, P; Mahner, S; Redondo, A; Lesoin, A; Colombo, N; Vergote, I; Rosengarten, O; Ledermann, J; Pineda, M; Ellard, S; Sehouli, J; Gonzalez-Martin, A; Berton-Rigaud, D; Madry, R; Reinthaller, A; Hazard, S; Guo, W Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1784 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗